ROR2/WNT5A upregulation could be advantageous to cancers driven by non-canonical Wnt signalling, while their epigenetic downregulation would benefit tumours, such as colon and haematopoietic cancers, that are driven by canonical Wnt signalling. The gene discussed is ROR2; the disease is hematopoietic and lymphoid cell neoplasm.